GlobeNewswire Inc.··Can-Fite Biopharma Ltd.Can-Fite's Namodenoson Clears Safety Hurdle in Pancreatic Cancer Study
Can-Fite's namodenoson meets primary safety endpoint in Phase IIa pancreatic cancer trial with no new safety signals; survival data pending.
CANFclinical developmentorphan drug designation